TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product.
The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency. CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.
Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in the chronic setting as well and is also involved in the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI.
The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS). TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.
Please dial one of the following numbers to participate:
Belgium: +32 (0) 2404 0662
Canada: +1 514 841 2154
France: +33 (0) 1 76 77 22 26
Netherlands: +31 (0) 20 716 8257
Spain: +34 91 453 3445
Sweden: +46 (0) 8 5065 3936
United Kingdom: +44 (0) 20 3427 1900
United States of America: +1 646 254 3365
Confirmation code: 8585083
The webcast can be followed live online via the link: http://edge.media-server.com/m/p/kvidxhyn